Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma: Wishing away the clouds - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Dec 23, 2000

    Sun Pharma: Wishing away the clouds

    It has been one of India’s fastest growing pharmaceutical companies. Over the last two years it has managed to grow its topline by over 30 percent year on year when the overall pharma industry has grown by not more than 12 percent per annum. Last year the company achieved a 33 percent growth in turnover, a 20 percent pretax margin and a return on networth of 24 percent. A fantastic performance by any standard. The company in question: Sun Pharma. Let’s take a look at what’s behind the company’s success.

    Sun Pharma adopted a three pronged approach over the last five years. First of all, it focussed its energies on the relatively faster growing therapeutic areas. Second, it adopted the acquisition route for building a critical mass. And finally, it has been very aggressive in new product launches which not only enables to keep its exposure to the Drug Price Control Order (DPCO) to the minimum but also enables it to charge higher prices for its products.

    Sun Pharmaceuticals manufactures formulations in niche segments such as psychiatry, cardiovascular, gastroentology and neurology. These segments are among the faster growing segments of the pharma industry. While most of the top Indian companies have focussed on antibiotics and anti–infectives, Sun Pharma focused on therapeutic areas such as depression, hypertension and cancer.

    Sun has also been extremely aggressive in the launch of new products with almost 24 new product launches in its niche areas, slated for the current year itself (10 of these have already been launched). These are expected to help the company achieve at least a 25 percent growth in the coming year too. The company derives almost 40 percent of its revenues from products introduced in the past five years. Consequently its exposure to revenues accruing from products under the DPCO is a relatively low 19 percent of domestic formulation sales.

    Over the years Sun has used the strategy of acquisitions and mergers to grow quickly. It acquired Knoll Pharma’s bulk drug facility, Gujarat Lyka Organics, 51.5 percent in M. J. Pharma, merged Tamil Nadu Dadha Pharma, acquired Natco’s brands and merged Milmet Labs.

    Perhaps the only area of concern is the continuing losses of its US based affiliate Caraco Pharma, which is the company’s vehicle for launch of generics. Sun has invested US$ 12.8 m – US$ 7.5 m towards equity and US$ 5.3 m towards debt in Caraco, which has registered a loss of over US$ 9.7 m for the year ended December 1999. This loss however includes the US$ 6.3 m that were incurred for R&D related to product filings. Caraco has submitted around nine abbreviated new drug applications (ANDA) which are awaiting US FDA approval. These are expected to come through in the first quarter of the calendar year 2001. The company has also clarified that the primary reason for continuing losses at Caraco is the delay in receiving approvals from the US FDA. Most of these products are relatively more complex and the company foresees relatively lower competition for these products in the generic market. Infact, Sun intends to build a clearly differentiated line of generics where margin erosions are not that steep. Over a period of time it intends to move up the value chain to branded generics that offer a products/technology/delivery advantage. Keeping in view the extensive consolidation that is expected to take place in the US generic market, this may be the best option to create long term value.

    In the current year too, Caraco is expected to report a loss of US$ 5–6 million. It is expected to break even only in the later half of next year. Sun Pharma has however, not provided for this diminution in the value of its investments in its books.

    So far Sun has relied on reverse engineering the products patented abroad. However, post 2005 it would have to develop its own New Chemical Entities (NCEs). The company has already initiated research in three therapeutic areas for developing NCEs. The management however, refuses to specify which are these therapeutic areas.

    This aside, in the short term at least (until 2005) the company’s outlook seems promising. Sun Pharma is expected to post a net profit of Rs 1,134 million in the fiscal year 2001 (a 25 percent growth over 2000). The company also expects its topline to continue growing at a compounded annual growth rate 25 percent over the next two years. Bottomline, there is shine in this Sun.



    Equitymaster requests your view! Post a comment on "Sun Pharma: Wishing away the clouds". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

    Mar 11, 2017

    Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

    Aug 4, 2017

    The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 17, 2017 12:14 PM


    • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Detailed Quarterly Results With Charts